Disruption of the Neurovascular Unit in Diabetic Retinopathy: Molecular Pathways and Tailored Therapeutic Approaches for Different Stages
-
By
-
Jing Chen
-
Ling Zhang
-
July 1, 2026
Clinical Report: Disruption of the Neurovascular Unit in Diabetic Retinopathy
Overview
Diabetic retinopathy (DR) is increasingly recognized as a neurovascular degenerative disorder, with early neuronal dysfunction preceding visible vascular lesions. This review discusses the molecular pathways involved in DR.
Background
Diabetic retinopathy is a significant cause of vision loss among adults, affecting over 100 million individuals globally. Traditionally viewed as a microvascular complication, recent insights reveal that DR involves interactions among neuronal, glial, and vascular components of the retinal neurovascular unit.
Data Highlights
No numerical data provided in the article.
Key Findings
- Diabetic retinopathy is a neurovascular degenerative disorder, not solely a microvascular complication.
- Chronic hyperglycemia and oxidative stress disrupt the retinal neurovascular unit, leading to neurovascular uncoupling.
- Functional abnormalities in DR can occur before visible vascular lesions are detected.
- Current therapies primarily target advanced disease.
Clinical Implications
Recognizing diabetic retinopathy as a disorder of the neurovascular unit may facilitate earlier diagnosis.
Conclusion
Reframing diabetic retinopathy as a neurovascular disorder emphasizes the importance of early detection.
Related Resources & Content
- Retinal Physician, New Strategies for Managing Diabetic Retinopathy, 2026
- The Ophthalmologist, Resveratrol and Diabetic Retinopathy, 2026
- Optometric Management, Staging and Practical Management of Diabetic Retinopathy, 2026
- Diabetes Care, 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
- Retinal Physician — New Pathways for Diabetic Macular Edema Therapy
- Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 - PMC
- Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology
- EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE
- Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy - PMC
- Effect of Aflibercept, Laser Photocoagulation, or Observation on Vision Loss in Diabetic Macular Edema
- IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS - PubMed
- Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials - PMC
- Diabetic retinopathy: management and monitoring - NCBI Bookshelf
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
Based on findings from:
Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies
Jing Chen, Ling Zhang. Frontiers In Endocrinology, 2026.
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1896091/full
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
